Ligand outlines 23% CAGR royalty growth outlook through 2030 as royalty portfolio accelerates
Source: SeekingAlpha
2026-02-26 17:48:22 ET
More on Ligand Pharmaceuticals
- Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript
- Ligand Pharmaceuticals: 2026 Guidance May Already Be Included In Current Valuation
- Ligand Pharmaceuticals Incorporated (LGND) Analyst/Investor Day Transcript
- Ligand Pharmaceuticals Non-GAAP EPS of $2.02 beats by $0.52, revenue of $59.7M beats by $4.11M
- Ligand Pharmaceuticals Q4 2025 Earnings Preview
Read the full article on Seeking Alpha
For further details see:
Ligand outlines 23% CAGR royalty growth outlook through 2030 as royalty portfolio accelerates
Ligand Pharms Glucagon
NASDAQ: LGNXZ
LGNXZ Trading
0.96% G/L:
$0.0021 Last:
100 Volume:
$0.00208 Open:
LGNXZ Latest News
LGNXZ Stock Data
$3,679,103,920
18,304,000
N/A
151
N/A
Biotechnology & Life Sciences
Healthcare
US
Jupiter
